Role of Optical Coherence Tomography in the Prognosis of Vogt–Koyanagi–Harada Disease

ABSTRACT Purpose: To evaluate the prognostic value of OCT in acute VKH disease Methods: Retrospective series of consecutive VKH patients seen with the first presentation, a minimum follow-up of 1 year and serial OCT imaging. The primary outcome was the clinical activity phase at 1, 2 and 3 years. Results: Among 29 subjects, 7 resolved, 17 became chronic, and 5 developed chronic recurrent VKH. Median RNFL measurement obtained 2 months post-treatment was higher among subjects who developed chronic VKH (p-value = 0.03) and chronic recurrent disease (p-value = 0.04). Median CRT 1-week post-treatment was lower among subjects who developed PPA (p-value = 0.03). CRT 2 months post-treatment was higher among subjects who developed vitiligo (p-value = 0.02). Conclusion: OCT is helpful in early recognition of the predominantly optic disc swelling variant which carries a poorer prognosis. Lower CRT reading at 1 week and persistently raised CRT at 2 months post-treatment correlated with chronic recurrent disease.

[1]  A. Okada,et al.  Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids , 2018, British Journal of Ophthalmology.

[2]  Q. Chang,et al.  Differences in photoreceptor recovery among patients and between different parts of the posterior pole in Vogt–Koyanagi–Harada disease , 2017, Eye.

[3]  Tomohiro Ikeda,et al.  Detection of Asymptomatic Choroiditis by Fundus Examination in Vogt–Koyanagi–Harada Disease , 2017, Ocular immunology and inflammation.

[4]  S. Chee,et al.  Comparison of Enhanced Depth Imaging and Swept Source Optical Coherence Tomography in Assessment of Choroidal Thickness in Vogt–Koyanagi–Harada Disease , 2017, Ocular immunology and inflammation.

[5]  A. Schlaen,et al.  Spectrum and visual outcomes of Vogt-Koyanagi-Harada disease in Argentina. , 2017, International journal of ophthalmology.

[6]  M. Khairallah,et al.  Reappraisal of the management of Vogt–Koyanagi–Harada disease: sunset glow fundus is no more a fatality , 2016, International Ophthalmology.

[7]  T. Porco,et al.  Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies. , 2016, American journal of ophthalmology.

[8]  V. Sakata,et al.  Fundus autofluorescence as a marker of disease severity in Vogt–Koyanagi–Harada disease , 2016, Acta ophthalmologica.

[9]  D. Kurosaka,et al.  RETINAL PIGMENT EPITHELIUM UNDULATIONS IN ACUTE STAGE OF VOGT-KOYANAGI-HARADA DISEASE: Biomarker for Functional Outcomes After High-Dose Steroid Therapy , 2016, Retina.

[10]  H. Gatica,et al.  Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt‐Koyanagi‐Harada disease , 2015, Acta ophthalmologica.

[11]  K. Nishida,et al.  Analysis of choroidal folds in acute Vogt–Koyanagi–Harada disease using high-penetration optical coherence tomography , 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.

[12]  H. Goto,et al.  Differences in the clinical features of two types of Vogt-Koyanagi-Harada disease: serous retinal detachment and optic disc swelling , 2015, Japanese Journal of Ophthalmology.

[13]  M. Hangai,et al.  Relationship between retinal lesions and inward choroidal bulging in Vogt-Koyanagi-Harada disease. , 2014, American journal of ophthalmology.

[14]  H. Al‐Mezaine,et al.  Prognostic factors for clinical outcomes in patients with Vogt–Koyanagi–Harada disease treated with high‐dose corticosteroids , 2013, Acta ophthalmologica.

[15]  S. Chee,et al.  The outcomes of indocyanine green angiography monitored immunotherapy in Vogt–Koyanagi–Harada disease , 2012, British Journal of Ophthalmology.

[16]  H. Al‐Mezaine,et al.  The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt–Koyanagi–Harada disease , 2012, Acta ophthalmologica.

[17]  A. Okada,et al.  ENHANCED DEPTH IMAGING OPTICAL COHERENCE TOMOGRAPHY OF THE CHOROID IN VOGT–KOYANAGI–HARADA DISEASE , 2012, Retina.

[18]  C. Cheung,et al.  The prognostic value of angiography in Vogt-Koyanagi-Harada disease. , 2010, American journal of ophthalmology.

[19]  M. Hangai,et al.  Acute Vogt-Koyanagi-Harada disease in enhanced spectral-domain optical coherence tomography. , 2009, Ophthalmology.

[20]  Chan Zhao,et al.  Choroidal Folds in Acute Vogt-Koyanagi-Harada Disease , 2009, Ocular immunology and inflammation.

[21]  S. Chee,et al.  Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore. , 2009, American journal of ophthalmology.

[22]  F. Wen,et al.  Choroidal folds in Vogt-Koyanagi-Harada disease. , 2007, American journal of ophthalmology.

[23]  Y. Akova,et al.  The spectrum of Vogt-Koyanagi-Harada disease in Turkey , 2007, International Ophthalmology.

[24]  Douglas A Jabs,et al.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. , 2005, American journal of ophthalmology.

[25]  C. Luu,et al.  Visual function in Vogt-Koyanagi-Harada patients , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[26]  S. Ohno,et al.  Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. , 2001, American journal of ophthalmology.

[27]  K. Norose,et al.  Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. , 1996, The British journal of ophthalmology.

[28]  M. Mochizuki,et al.  Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease. , 1996, International immunology.